Human Life CORD
JAPAN

News Release

October 27, 2026

Human Life CORD Advances Cell Therapy Business in the Philippines

Completes Technical Support and Training in Japan, Moving Toward Local Manufacturing and Commercialization

Human Life CORD Japan Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Masamitsu Harata; hereinafter "HLC"), a clinical-stage Japanese biotechnology company developing regenerative cell therapies based on umbilical cord–derived mesenchymal stromal cells (UC-MSCs), announces that it has achieved a contractual milestone under its business partnership with Cordtech Medical Inc. (President and CEO: Emil Hiroaki Banno; Muntinlupa City, Philippines; hereinafter "Cordtech"). The milestone was achieved through the completion of the provision of technical information relating to HLC's proprietary UC-MSC manufacturing technology, as well as technical support and training conducted in Japan. As a result, HLC has received a milestone payment, the amount of which has not been disclosed.

HLC and Cordtech have been advancing their collaboration in phases, with the aim of developing, manufacturing, and commercializing UC-MSC products in the Philippines. Under this partnership, HLC is responsible for providing UC-MSC manufacturing technology and know-how, as well as technical support and training related to manufacturing facility development and quality management. Cordtech is responsible for local product development, manufacturing, and sales. HLC is entitled to receive multiple milestone payments from Cordtech as commercialization progresses, followed by agreed royalties based on Cordtech's sales once commercial sales commence.

Building on this milestone, the two companies will move forward with establishing manufacturing facilities and quality management systems in the Philippines, while continuing technical support and training locally to advance the commercialization of UC-MSC products.

Background and Significance of Business Expansion in the Philippines

The Philippines continues to experience economic development alongside the gradual aging of its population, creating increasingly diverse healthcare needs, including those associated with age-related declines in physical function and chronic diseases.

Against this backdrop, there is growing interest in the potential of cell therapies as new treatment options in the Philippines. In response to these local needs, HLC aims to establish a manufacturing and business foundation for cell therapy products in the Philippines through its collaboration with Cordtech, leveraging its proprietary UC-MSC manufacturing and quality management technologies and development experience cultivated in Japan.

Building on its Japan-originated quality and technology platform, HLC has been pursuing the global expansion of its umbilical cord-derived cell therapy business in the United States, the United Arab Emirates (UAE), and the Middle East and North Africa (MENA) region. With the Philippines now joining these markets, HLC intends to further accelerate the development of its global ecosystem for umbilical cord-derived cell therapies.

■ About Human Life CORD Japan Inc. (https://humanlifecord.com/en/)

Human Life CORD Japan Inc. (HLC) is developing novel cell therapy products for clinical use derived from domestically sourced, stockpiled umbilical cords, thereby providing hope to patients suffering from intractable diseases for which no established treatments are currently available. Looking ahead, HLC is committed to advancing its vision to create a world where everyone can live a rich and fulfilling life with healthy life expectancy, through providing future healthcare aimed at preventing disease progression. In recognition of our efforts, HLC have received numerous awards and distinctions: The Grand Prize & Tokyo Metropolitan Governor's Award at the "First Tokyo Venture Corporate Championship Conference" (2019); selected as a beneficiary in the "Deep Ecosystem" program of the Tokyo Metropolitan Government "Start-up Ecosystem Tokyo Consortium"; the Minister of Health, Labour and Welfare Award at the 5th Japan Open Innovation Prize hosted by the Cabinet Office in 2023; selected by the Ministry of Economy, Trade and Industry (METI) for its J-Startup support program in 2023; the Grand Prize in the Startup Category at the Courageous Management Awards (2024), organized by the Tokyo Chamber of Commerce and Industry; selected for the 2026 "SusHi Tech Global Startups" program by the Tokyo Metropolitan Government, an initiative dedicated to accelerating the international growth of high-potential innovators.

Contact:

Human Life CORD Japan Inc.

Public Relations; info@humanlifecord.com